Finance

Beta
Lists
STRO:NASDAQ
Sutro Biopharma Inc
$26.09
-9.03%
(-2.59) 1D
$26.09
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for STRO...
Open
$28.47
High
$28.73
Low
$25.80
Mkt. cap
432.32M
Avg. vol.
308.90K
Volume
295.74K
52-wk high
$43.85
52-wk low
$6.74
EPS
-$16.35
Beta
1.54
Shares outstanding
16.57M
No. of employees
133
Open
$28.47
High
$28.73
Low
$25.80
Mkt. cap
432.32M
Avg. vol.
308.90K
Volume
295.74K
52-wk high
$43.85
52-wk low
$6.74
EPS
-$16.35
Beta
1.54
Shares outstanding
16.57M
No. of employees
133
Analyst outlook
Analyst Ratings
Based on 11 analysts giving stock ratings to STRO in the past 3 months
Strong Buy
Buy
10
Hold
0
Sell
1
12 month forecast
Based on 11 Wall Street analysts offering 12 month price targets for STRO in the last 3 months.
Highest
Current $26.09
$60.00 (+129.97%)
Average
$48.44 (+85.67%)
Lowest
$27.00 (+3.49%)
News stories
From sources across the web
Profile
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Wikipedia
About Sutro Biopharma Inc
CEO-
Employees133
Founded2003
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitesutrobio.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
63.74M
9.69M
11.65M
14.52M
Cost of goods sold
38.32M
39.85M
36.64M
801.00K
Cost of revenue
38.32M
39.85M
36.64M
801.00K
Research and development expenses
-
-
-
35.75M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.34M
8.74M
8.66M
7.58M
Operating expense
10.34M
8.74M
8.66M
43.34M
Total operating expenses
48.67M
48.59M
45.30M
44.14M
Operating income
15.08M
-38.90M
-33.66M
-29.61M
Other non operating income
-
-
-
-
EBT including unusual items
-11.52M
-56.86M
-46.84M
-38.50M
EBT excluding unusual items
6.90M
-47.30M
-42.45M
-38.46M
Income tax expense
-18.00K
-
-82.00K
-15.00K
Effective tax rate
0.16%
-
0.17%
0.04%
Other operating expenses
-
-
-
-
Net income
-11.50M
-56.86M
-46.76M
-38.48M
Net profit margin
-18.04%
-586.58%
-401.49%
-264.99%
Earnings per share
-1.40
-5.57
-4.88
-2.94
Interest and investment income
2.52M
2.01M
1.53M
1.64M
Interest expense
-10.69M
-10.41M
-10.33M
-10.48M
Net interest expenses
-8.17M
-8.40M
-8.80M
-8.84M
Depreciation and amortization charges
-
-
-
-
EBITDA
16.98M
-37.00M
-32.03M
-28.34M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer